{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:55:21Z","timestamp":1786985721933,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.carrev.2021.07.017","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T19:14:59Z","timestamp":1626981299000},"page":"106-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years"],"prefix":"10.1016","volume":"38","author":[{"given":"Michael","family":"Haude","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Toelg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Alves","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evald H\u00f8j","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Abizaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"von Birgelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Teik","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Escaned","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eeckhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector M.","family":"Garcia-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2021.07.017_bb0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2016.11.055","article-title":"10-Year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents","volume":"69","author":"Gall\u00f8e","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2021.07.017_bb0010","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","article-title":"Stent-related adverse events >1 year after percutaneous coronary intervention","volume":"75","author":"Madhavan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2021.07.017_bb0015","doi-asserted-by":"crossref","first-page":"S923","DOI":"10.21037\/jtd.2017.06.30","article-title":"Mechanical behavior of polymer-based vs. metallic-based bioresorbable stents","volume":"9","author":"Ang","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.carrev.2021.07.017_bb0020","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.4244\/EIJ20170912-01","article-title":"Report of an ESC-EAPCI task force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary","volume":"13","author":"Byrne","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2021.07.017_bb0025","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamacardio.2019.4101","article-title":"Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study","volume":"4","author":"Stone","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.carrev.2021.07.017_bb0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.carrev.2016.05.001","article-title":"In vitro performance investigation of bioresorbable scaffolds - standard tests for vascular stents and beyond","volume":"17","author":"Schmidt","year":"2016","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2021.07.017_bb0035","first-page":"E502","article-title":"Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III","volume":"92","author":"Haude","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2021.07.017_bb0040","doi-asserted-by":"crossref","unstructured":"Haude M, Ince H, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo coronary lesions: three-year clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. EuroIntervention 2020;15:e1375-e82.","DOI":"10.4244\/EIJ-D-18-01000"},{"key":"10.1016\/j.carrev.2021.07.017_bb0045","doi-asserted-by":"crossref","unstructured":"Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet (London, England). 2016;387:31\u20139.","DOI":"10.1016\/S0140-6736(15)00447-X"},{"key":"10.1016\/j.carrev.2021.07.017_bb0050","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation."},{"key":"10.1016\/j.carrev.2021.07.017_bb0055","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4244\/EIJV5I7A146","article-title":"Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies","volume":"5","author":"Vranckx","year":"2010","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2021.07.017_bb0060","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2013.08.720","article-title":"Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI)","volume":"62","author":"Moussa","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2021.07.017_bb0065","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.21037\/atm-20-5668","article-title":"Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study","volume":"8","author":"Wu","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.carrev.2021.07.017_bb0070","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial","volume":"11","author":"Lef\u00e8vre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2021.07.017_bb0075","doi-asserted-by":"crossref","unstructured":"Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, et al. Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials. EuroIntervention 2018;13:e2147-e51.","DOI":"10.4244\/EIJ-D-17-00230"},{"key":"10.1016\/j.carrev.2021.07.017_bb0080","doi-asserted-by":"crossref","unstructured":"Wijns W, Valdes-Chavarri M, Richardt G, Moreno R, \u00cd\u00f1iguez-Romo A, Barbato E, et al. Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. EuroIntervention 2018;14:e343-e51.","DOI":"10.4244\/EIJ-D-18-00358"},{"key":"10.1016\/j.carrev.2021.07.017_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcin.2017.11.031","article-title":"5-Year outcome following randomized treatment of all-comers with Zotarolimus-eluting resolute integrity and Everolimus-eluting PROMUS element coronary stents","volume":"11","author":"Zocca","year":"2018","journal-title":"Final Report of the DUTCH PEERS (TWENTE II) Trial JACC cardiovascular interventions"},{"key":"10.1016\/j.carrev.2021.07.017_bb0090","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacc.2015.11.051","article-title":"Safety and efficacy of Everolimus- versus Sirolimus-eluting stents: 5-year results from SORT OUT IV","volume":"67","author":"Jensen","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2021.07.017_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamacardio.2016.5190","article-title":"Five-year outcome after implantation of Zotarolimus- and Everolimus-eluting stents in randomized trial participants and nonenrolled eligible patients: a secondary analysis of a randomized clinical trial","volume":"2","author":"von Birgelen","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.carrev.2021.07.017_bb0100","doi-asserted-by":"crossref","unstructured":"Verheye S, Wlodarczak A, Montorsi P, Torzewski J, Bennett J, Haude M, et al. BIOSOLVE-IV-registry: safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. Catheter Cardiovasc Interv 2021;98:E1-E8.","DOI":"10.1002\/ccd.29260"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838921005443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838921005443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:22:43Z","timestamp":1761560563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838921005443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":20,"alternative-id":["S1553838921005443"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2021.07.017","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2021.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}